← All indications
Neoplasms, Plasma Cell
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Subtype terms (4)
More specific conditions that are subtypes of Neoplasms, Plasma Cell in the MeSH hierarchy.
- Immunoglobulin Light-chain Amyloidosis
59 drugs (43 approved, 16 experimental)
- Multiple Myeloma
992 drugs (335 approved, 657 experimental)
- Plasmacytoma
92 drugs (60 approved, 32 experimental)
- Waldenstrom Macroglobulinemia
181 drugs (98 approved, 83 experimental)
Drugs by status
Phase 4 trials (2)
Phase 3 trials (2)
Phase 2 trials (31)
- allopurinol
- busulfan
- diphenhydramine
- tacrolimus
- naltrexone
- hemopoietic stem cell
- allogeneic stem cells
- acetaminophen
- immune globulin (human)
- Isatuximab
- cyclosporine
- mycophenolate
- cyclophosphamide
- stem cells
- allogeneic lymphocytes
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- autologous cd34+ cells
- autologous mononuclear stem cell
- fludarabine
- daratumumab
- sargramostim
- melphalan
- pomalidomide
- ranitidine
- dexamethasone
- nirogacestat
- belantamab mafodotin
- bcma-pd1-cart cell
- ciltacabtagene autoleucel
- +1 more
Phase 1 trials (13)
Organizations
Organization Involved with Phase 4 Indications (39)
- Sun Yat-Sen University
- Emory University
- University of Nice Sophia Antipolis
- Second Military Medical University
- Peking University
- Jiao Tong University
- Zhejiang University
- Bristol-Myers Squibb
- Harbin Medical University
- Sanofi
- Biovitrum AB
- Chinese Academy of Medical Sciences
- Belarusian State Medical University
- Shanxi Medical University
- University of Maryland
- Central South University
- Fujian Medical University
- University of Turin
- University of Baghdad
- Swedish Orphan Biovitrum
- Government of Spain
- People's Liberation Army of China
- Novartis
- Capital Medical University
- Harvard University
- Minsk State Clinical Hospital No 9
- Johnson and Johnson
- Millennium Pharmaceuticals
- Osakidetza
- Amgen
- +9 more
Organization Involved with Phase 3 Indications (221)
- Jinlin University
- Freeman Health System
- University of Minnesota
- Oregon Health and Science University
- Medical College of Wisconsin
- Utrecht University
- Newton-Wellesley Hospital
- European Group for Blood and Marrow Transplantation
- European Organisation for Research and Treatment of Cancer
- Stanford University
- HOVON - Dutch Haemato-Oncology Association
- Abbott
- Cornell University
- University of Poitiers
- International Myeloma Foundation (IMF)
- Wuezburg University Hospital
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- University of California, Los Angeles
- Hospital Clinico Madrid
- University of Rochester
- Washington University in St. Louis
- University of Ankara
- National University of Singapore
- Jingjiang People's Hospital
- Roche
- Duke University
- Université de La Réunion
- Zhangjiagang First People's Hospital
- University of Leipzig
- Janssen Pharmaceutica NV
- +191 more
Organization Involved with Phase 2 Indications (320)
- Xcyte Therapies
- University of Freiburg
- Peter MacCallum Cancer Centre
- AmpliMed Corporation
- Free University of Amsterdam
- Centre Hospitalier de Blois -BLOIS
- Sirtris Pharmaceuticals
- Cantonal Hospital of St. Gallen
- Sponsor GmbH
- National Taiwan University
- Ludwig Maximilians University
- RWTH Aachen University
- Department of Veteran Affairs
- Taipei Veteran General hospital
- University of Helsinki
- University of Louisville
- Korea Research Institute of Bioscience & Biotechnology
- Kleo Pharmaceuticals
- Our Lady of Mercy Medical Center
- TFS Trial Form Support
- University of Turku
- Central Hospital of Kanta-Hame
- Karolinska Institute
- Polyphor Ltd.
- Threshold Pharmaceuticals
- University of Connecticut
- University of Birmingham
- Nij Smellinghe Hospital Drachten
- Prolexys Pharmaceuticals
- Government of Finland
- +290 more
Organization Involved with Phase 1 Indications (106)
- Ionis Pharmaceuticals, Inc.
- Chong Kun Dang Pharmaceutical
- Aevi Genomic Medicine
- Cougar Biotechnology
- Trillium Therapeutics Inc.
- University of Arkansas
- Yake Biotechnology Ltd.
- AVEO Pharmaceuticals
- Corvus Pharmaceuticals, Inc.
- HonorHealth Research Institute
- City University of Hong Kong
- Oncolytics Biotech
- JW Pharmaceutical
- Leadiant Biosciences, Inc.
- CLL Global Research Foundation
- Cantex Pharmaceuticals
- Benovus Bio, Inc.
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Sorrento Therapeutics, Inc.
- Phylogeny
- Allogene Therapeutics
- Anhui Medical University
- Technical University of Dresden
- Merck Serono
- Chugai
- Hebei Senlang Biotechnology Inc., Ltd.
- Tmunity Therapeutics
- Facet Biotech
- Leap Therapeutics, Inc.
- bluebird bio
- +76 more
Organization Involved with Other Experimental Indications (7)